1
|
Kremer K, Schwarz-Selinger T, Jacob W. Deuterium plasma exposure of thin oxide films on tungsten - Oxygen removal and deuterium uptake. Nuclear Materials and Energy 2023. [DOI: 10.1016/j.nme.2023.101406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/07/2023]
|
2
|
Kärcher A, Schwarz-Selinger T, Burwitz V, Mathes L, Hugenschmidt C, Jacob W. The influence of displacement damage on helium uptake and retention in tungsten. Nuclear Materials and Energy 2023. [DOI: 10.1016/j.nme.2023.101370] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
3
|
Gomez-Roca C, Cassier P, Zamarin D, Machiels JP, Luis Perez Gracia J, Stephen Hodi F, Taus A, Martinez Garcia M, Boni V, Eder JP, Hafez N, Sullivan R, Mcdermott D, Champiat S, Aspeslagh S, Terret C, Jegg AM, Jacob W, Cannarile MA, Ries C, Korski K, Michielin F, Christen R, Babitzki G, Watson C, Meneses-Lorente G, Weisser M, Rüttinger D, Delord JP, Marabelle A. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade. J Immunother Cancer 2022; 10:jitc-2021-004076. [PMID: 35577503 PMCID: PMC9114963 DOI: 10.1136/jitc-2021-004076] [Citation(s) in RCA: 30] [Impact Index Per Article: 15.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/08/2022] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND This phase 1b study (NCT02323191) evaluated the safety, antitumor activity, pharmacokinetics, and pharmacodynamics of colony-stimulating factor-1 receptor-blocking monoclonal antibody (mAb) emactuzumab in combination with the programmed cell death-1 ligand (PD-L1)-blocking mAb atezolizumab in patients with advanced solid tumors naïve or experienced for immune checkpoint blockers (ICBs). METHODS Emactuzumab (500-1350 mg flat) and atezolizumab (1200 mg flat) were administered intravenously every 3 weeks. Dose escalation of emactuzumab was conducted using the 3+3 design up to the maximum tolerated dose (MTD) or optimal biological dose (OBD). Extension cohorts to evaluate pharmacodynamics and clinical activity were conducted in metastatic ICB-naive urothelial bladder cancer (UBC) and ICB-pretreated melanoma (MEL), non-small cell lung cancer (NSCLC) and UBC patients. RESULTS Overall, 221 patients were treated. No MTD was reached and the OBD was determined at 1000 mg of emactuzumab in combination with 1200 mg of atezolizumab. Grade ≥3 treatment-related adverse events occurred in 25 (11.3%) patients of which fatigue and rash were the most common (14 patients (6.3%) each). The confirmed objective response rate (ORR) was 9.8% for ICB-naïve UBC, 12.5% for ICB-experienced NSCLC, 8.3% for ICB-experienced UBC and 5.6% for ICB-experienced MEL patients, respectively. Tumor biopsy analyses demonstrated increased activated CD8 +tumor infiltrating T lymphocytes (TILs) associated with clinical benefit in ICB-naïve UBC patients and less tumor-associated macrophage (TAM) reduction in ICB-experienced compared with ICB-naïve patients. CONCLUSION Emactuzumab in combination with atezolizumab demonstrated a manageable safety profile with increased fatigue and skin rash over usual atezolizumab monotherapy. A considerable ORR was particularly seen in ICB-experienced NSCLC patients. Increase ofCD8 +TILs under therapy appeared to be associated with persistence of a TAM subpopulation.
Collapse
Affiliation(s)
- Carlos Gomez-Roca
- Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France
| | | | - Dmitriy Zamarin
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Jean-Pascal Machiels
- Department of Medical Oncology, Cliniques Universitaires Saint-Luc, Bruxelles, Belgium
| | | | - F Stephen Hodi
- Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
| | - Alvaro Taus
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
| | | | - Valentina Boni
- Medical Oncology, Hospital Universitario HM Sanchinarro, Madrid, Spain
| | - Joseph P Eder
- Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA
| | - Navid Hafez
- Department of Medical Oncology, Yale University Yale Cancer Center, New Haven, Connecticut, USA
| | - Ryan Sullivan
- Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA
| | - David Mcdermott
- Division of Hematology/Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Stephane Champiat
- Drug Development Department, Gustave Roussy Institute, Villejuif, France
| | - Sandrine Aspeslagh
- Drug Development Department, Gustave Roussy Institute, Villejuif, France
| | | | | | | | | | - Carola Ries
- Roche Innovation Center Munich, Penzberg, Germany
| | | | | | | | | | | | | | | | | | - Jean-Pierre Delord
- Department of Medical Oncology and Clinical Research Unit, Institut Claudius Regaud, Toulouse, France
| | - Aurelien Marabelle
- Drug Development Department, Gustave Roussy Institute, Villejuif, France
| |
Collapse
|
4
|
Arredondo R, Balden M, Schwarz-Selinger T, Höschen T, Dürbeck T, Hunger K, Schlueter K, Golubeva A, Wang P, Terentyev D, Jacob W. Comparison experiment on the sputtering of EUROFER, RUSFER and CLAM steels by deuterium ions. Nuclear Materials and Energy 2022. [DOI: 10.1016/j.nme.2022.101118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Kremer K, Brucker M, Jacob W, Schwarz-Selinger T. Influence of thin surface oxide films on hydrogen isotope release from ion-irradiated tungsten. Nuclear Materials and Energy 2022. [DOI: 10.1016/j.nme.2022.101137] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
6
|
Magalhães N, Waitzberg D, Vicedomini A, Lopes N, Jacob W, Busse A, Alves T, Ferdinando D, Torrinhas R, Belarmino G. Factors associated with the elderly quality of life: dietary pattern, body composition and cognition. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.569] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
7
|
Lopes N, Waitzberg D, Vicedomini A, Magalhães N, Jacob W, Busse A, Alves T, Ferdinando D, Belarmino G. SARC-F and sarc-calf performance for screening sarcopenia in elderly Brazilians. Clin Nutr ESPEN 2021. [DOI: 10.1016/j.clnesp.2021.09.552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
8
|
Kremer K, Schwarz-Selinger T, Jacob W. Influence of thin tungsten oxide films on hydrogen isotope uptake and retention in tungsten – Evidence for permeation barrier effect. Nuclear Materials and Energy 2021. [DOI: 10.1016/j.nme.2021.100991] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
Cassier PA, Italiano A, Gomez-Roca C, Le Tourneau C, Toulmonde M, D'Angelo SP, Weber K, Loirat D, Jacob W, Jegg AM, Michielin F, Christen R, Watson C, Cannarile M, Klaman I, Abiraj K, Ries CH, Weisser M, Rüttinger D, Blay JY, Delord JP. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour. Eur J Cancer 2020; 141:162-170. [PMID: 33161240 DOI: 10.1016/j.ejca.2020.09.038] [Citation(s) in RCA: 27] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2020] [Accepted: 09/28/2020] [Indexed: 10/23/2022]
Abstract
OBJECTIVES This study investigated the safety, clinical activity and patient-reported outcomes of patients with diffuse-type tenosynovial giant-cell tumour (dTGCT) of the soft tissue who were treated with emactuzumab, a humanised anti-colony stimulating factor 1 receptor (CSF1R) monoclonal antibody and were followed up for up to 2 years after the start of treatment. METHODS In this open-label phase 1 study (ClinicalTrials.govNCT01494688), patients received intravenous (IV) emactuzumab from 900 to 2000 mg every two weeks in the dose-escalation phase and at the optimal biological dose of 1000 mg with different schedules in the dose-expansion phase. Adverse event (AE) rates and biomarker assessments from tumour biopsies were analysed. Quality of life was assessed using a standard questionnaire (EuroQol-5D-3L) and the WOMAC® 3.1 Osteoarthritis Index. Tumour responses were determined with magnetic resonance imaging. RESULTS Altogether, 63 patients were enrolled into the study. The most frequently reported AEs were pruritus, asthenia and oedema. In 36 patients for whom biopsy tissue was available a substantial decrease of CSF1R-positive and CD68/CD163-positive macrophages was detected. The independently reviewed best overall objective response rate (ORR) (Response Evaluation Criteria in Solid Tumors version 1.1) was 71%. Responses were durable, and an ORR of 70% and 64% was determined after one or two years after enrolment into the study. Clinical activity was accompanied by an improvement in EuroQol-5D-3L and particularly the joint disorder-specific WOMAC score. CONCLUSIONS Systemic therapy of dTGCT patients with emactuzumab resulted in pronounced and durable responses associated with symptomatic improvement and a manageable safety profile.
Collapse
Affiliation(s)
| | | | - Carlos Gomez-Roca
- Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France
| | - Christophe Le Tourneau
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France; INSERM U900 Research Unit, Saint-Cloud, France; Paris-Saclay University, Paris, France
| | | | - Sandra P D'Angelo
- Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA
| | | | - Delphine Loirat
- Department of Drug Development and Innovation (D3i), Institut Curie, Paris & Saint-Cloud, France
| | - Wolfgang Jacob
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
| | - Anna-Maria Jegg
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Francesca Michielin
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Randolph Christen
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | | | - Michael Cannarile
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Irina Klaman
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Keelara Abiraj
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Carola H Ries
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Dominik Rüttinger
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Jean-Yves Blay
- Centre Léon Bérard, Département D'Oncologie Médicale, Lyon, France; Université Claude Bernard Lyon I, Lyon, France; Unicancer, Paris, France
| | - Jean-Pierre Delord
- Institut Claudius Regaud, Département D'Oncologie Médicale, Toulouse, France
| |
Collapse
|
10
|
Machiels JP, Gomez-Roca C, Michot JM, Zamarin D, Mitchell T, Catala G, Eberst L, Jacob W, Jegg AM, Cannarile MA, Watson C, Babitzki G, Korski K, Klaman I, Teixeira P, Hoves S, Ries C, Meneses-Lorente G, Michielin F, Christen R, Rüttinger D, Weisser M, Delord JP, Cassier P. Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. J Immunother Cancer 2020; 8:jitc-2020-001153. [PMID: 33097612 PMCID: PMC7590375 DOI: 10.1136/jitc-2020-001153] [Citation(s) in RCA: 34] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/21/2020] [Indexed: 12/14/2022] Open
Abstract
Background This phase Ib study evaluated the safety, clinical activity, pharmacokinetics, and pharmacodynamics (PD) of emactuzumab (anti-colony stimulating factor 1 receptor monoclonal antibody (mAb)) in combination with selicrelumab (agonistic cluster of differentiation 40 mAb) in patients with advanced solid tumors. Methods Both emactuzumab and selicrelumab were administered intravenously every 3 weeks and doses were concomitantly escalated (emactuzumab: 500 to 1000 mg flat; selicrelumab: 2 to 16 mg flat). Dose escalation was conducted using the product of independent beta probabilities dose-escalation design. PD analyzes were performed on peripheral blood samples and tumor/skin biopsies at baseline and on treatment. Clinical activity was evaluated using investigator-based and Response Evaluation Criteria In Solid Tumors V.1.1-based tumor assessments. Results Three dose-limiting toxicities (all infusion-related reactions (IRRs)) were observed at 8, 12 and 16 mg of selicrelumab together with 1000 mg of emactuzumab. The maximum tolerated dose was not reached at the predefined top doses of emactuzumab (1000 mg) and selicrelumab (16 mg). The most common adverse events were IRRs (75.7%), fatigue (54.1%), facial edema (37.8%), and increase in aspartate aminotransferase and creatinine phosphokinase (35.1% both). PD analyzes demonstrated an increase of Ki67+-activated CD8+ T cells accompanied by a decrease of B cells and the reduction of CD14Dim CD16bright monocytes in peripheral blood. The best objective clinical response was stable disease in 40.5% of patients. Conclusion Emactuzumab in combination with selicrelumab demonstrated a manageable safety profile and evidence of PD activity but did not translate into objective clinical responses. Trialregistration number NCT02760797.
Collapse
Affiliation(s)
- Jean-Pascal Machiels
- Medical Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium .,UCLouvain, Brussels, Belgium
| | - Carlos Gomez-Roca
- Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
| | - Jean-Marie Michot
- Department of Innovative Therapies and Early Phase trials (DITEP), Gustave Roussy, Villejuif, France
| | - Dmitriy Zamarin
- Memorial Sloan Kettering Cancer Center, New York City, New York, USA
| | - Tara Mitchell
- Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | - Gaetan Catala
- Medial Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | | | - Wolfgang Jacob
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Anna-Maria Jegg
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Michael A Cannarile
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | | | - Galina Babitzki
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Konstanty Korski
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Irina Klaman
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Priscila Teixeira
- Pharma Research and Early Development, Roche Innovation Center Welwyn, Welwyn Garden City, UK
| | - Sabine Hoves
- Roche Innovat Ctr Munich Oncol Discovery Pharma, Penzberg, Germany
| | - Carola Ries
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | | | - Francesca Michielin
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Randolph Christen
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Dominik Rüttinger
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | | | | |
Collapse
|
11
|
Arredondo R, Balden M, Mutzke A, von Toussaint U, Elgeti S, Höschen T, Schlueter K, Mayer M, Oberkofler M, Jacob W. Impact of surface enrichment and morphology on sputtering of EUROFER by deuterium. Nuclear Materials and Energy 2020. [DOI: 10.1016/j.nme.2020.100749] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Massone A, Manhard A, Jacob W, Drexler A, Ecker W, Hohenwarter A, Wurster S, Kiener D. An SEM compatible plasma cell for in situ studies of hydrogen-material interaction. Rev Sci Instrum 2020; 91:043705. [PMID: 32357725 DOI: 10.1063/1.5142043] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/10/2019] [Accepted: 03/25/2020] [Indexed: 06/11/2023]
Abstract
An in situ hydrogen (H) plasma charging and in situ observation method was developed to continuously charge materials, while tensile testing them inside a scanning electron microscope (SEM). The present work will introduce and validate the setup and showcase an application allowing high-resolution observation of H-material interactions in a Ni-based alloy, Alloy 718. The effect of charging time and pre-straining was investigated. Fracture surface observation showed the expected ductile microvoid coalescence behavior in the uncharged samples, while the charged ones displayed brittle intergranular and quasi-cleavage failure. With the in situ images, it was possible to monitor the sample deformation and correlate the different crack propagation rates with the load-elongation curves. H-charging reduced the material ductility, while increasing pre-strain decreased hydrogen embrittlement susceptibility due to the possible suppression of mechanical twinning during the tensile test and, therefore, a reduction in H concentration at grain and twin boundaries. All the presented results demonstrated the validity of the method and the possibility of in situ continuously charging of materials with H without presenting any technical risk for the SEM.
Collapse
Affiliation(s)
- A Massone
- Materials Center Leoben Forschungs GmbH, 8700 Leoben, Austria
| | - A Manhard
- Max-Planck-Institut für Plasmaphysik, Boltzmannstr. 2, D-85748 Garching, Germany
| | - W Jacob
- Max-Planck-Institut für Plasmaphysik, Boltzmannstr. 2, D-85748 Garching, Germany
| | - A Drexler
- Materials Center Leoben Forschungs GmbH, 8700 Leoben, Austria
| | - W Ecker
- Materials Center Leoben Forschungs GmbH, 8700 Leoben, Austria
| | - A Hohenwarter
- Department Materials Science, Chair of Materials Physics, Montanuniversität Leoben, 8700 Leoben, Austria
| | - S Wurster
- Erich Schmid Institute of Materials Science, 8700 Leoben, Austria
| | - D Kiener
- Department Materials Science, Chair of Materials Physics, Montanuniversität Leoben, 8700 Leoben, Austria
| |
Collapse
|
13
|
Gordon DT, Okuma K, DeVries JW, Fukuhara K, Jacob W, Kuriyama N, Li BW, Matsuda I, McMonagle K, Parr GD, Porter S, Strong S, Sugimoto T, Tsuji K, Wolf B. Determination of Total Dietary Fiber in Selected Foods Containing Resistant Maltodextrin by Enzymatic-Gravimetric Method and Liquid Chromatography: Collaborative Study. J AOAC Int 2019. [DOI: 10.1093/jaoac/85.2.435] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
A method was developed for determination of total dietary fiber (TDF) in foods containing resistant maltodextrin (RMD) which includes nondigestible carbohydrates that are not fully recovered as dietary fiber by conventional TDF methods such as AOAC 985.29 or 991.43. Because the average molecular weight (MW) of RMD is 2000 daltons, lower MW soluble dietary fiber components do not precipitate in 78% ethanol; therefore, RMD is not completely quantitated as dietary fiber by current AOAC methods. The accuracy and precision of the method was evaluated through an AOAC collaborative study. Ten laboratories participated and assayed 12 test portions (6 blind duplicates) containing RMD. The 6 test pairs ranged from 1.5 to 100% RMD. The method consisted of the following steps: (1) The insoluble dietary fiber (IDF) and high MW soluble dietary fiber (HMWSDF) were determined by AOAC 985.29. (2) Ion exchange resins were used to remove salts and proteins contained in the AOAC 985.29 filtrates (including ethanol and acetone). (3) The amount of low MWRMD (LMWRMD) in the filtrates were determined by liquid chromatography. (4) The TDF was calculated by summation of the IDF, HMWSDF, and LMWRMD fractions having nondigestible carbohydrates with a degree of polymerization of 3 and higher. Repeatability standard deviations (RSDr) were 1.33–7.46%, calculated by including outliers, and 1.33–6.10%, calculated by not including outliers. Reproducibility standard deviations (RSDR) were 2.48–9.39%, calculated by including outliers, and 1.79–9.39%, calculated by not including outliers. This method is recommended for adoption as Official First Action.
Collapse
Affiliation(s)
- Dennis T Gordon
- North Dakota State University, Department of Cereal Science, Harris Hall 110, Fargo, ND 58105
| | - Kazuhiro Okuma
- Matsutani Chemical Industry Co., Ltd., Research Laboratory, 5-3 Kitaitami, Itami City, Hyogo, Japan 664-8508
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Gomez-Roca CA, Italiano A, Le Tourneau C, Cassier PA, Toulmonde M, D'Angelo SP, Campone M, Weber KL, Loirat D, Cannarile MA, Jegg AM, Ries C, Christen R, Meneses-Lorente G, Jacob W, Klaman I, Ooi CH, Watson C, Wonde K, Reis B, Michielin F, Rüttinger D, Delord JP, Blay JY. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages. Ann Oncol 2019; 30:1381-1392. [PMID: 31114846 PMCID: PMC8887589 DOI: 10.1093/annonc/mdz163] [Citation(s) in RCA: 112] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 07/27/2023] Open
Abstract
BACKGROUND Emactuzumab is a monoclonal antibody against the colony-stimulating factor-1 receptor and targets tumor-associated macrophages (TAMs). This study assessed the safety, clinical activity, pharmacokinetics (PK) and pharmacodynamics (PD) of emactuzumab, as monotherapy and in combination with paclitaxel, in patients with advanced solid tumors. PATIENTS AND METHODS This open-label, phase Ia/b study comprised two parts (dose escalation and dose expansion), each containing two arms (emactuzumab, every 2 or 3 weeks, as monotherapy or in combination with paclitaxel 80 mg/m2 weekly). The dose-escalation part explored the maximum tolerated dose and optimal biological dose (OBD). The dose-expansion part extended the safety assessment and investigated the objective response rate. A PK/PD analysis of serial blood, skin and tumor biopsies was used to explore proof of mechanism and confirm the OBD. RESULTS No maximum tolerated dose was reached in either study arm, and the safety profile of emactuzumab alone and in combination does not appear to preclude its use. No patients receiving emactuzumab monotherapy showed an objective response; the objective response rate for emactuzumab in combination with paclitaxel was 7% across all doses. Skin macrophages rather than peripheral blood monocytes or circulating colony-stimulating factor-1 were identified as an optimal surrogate PD marker to select the OBD. Emactuzumab treatment alone and in combination with paclitaxel resulted in a plateau of immunosuppressive TAM reduction at the OBD of 1000 mg administered every 2 weeks. CONCLUSIONS Emactuzumab showed specific reduction of immunosuppressive TAMs at the OBD in both treatment arms but did not result in clinically relevant antitumor activity alone or in combination with paclitaxel. (ClinicalTrials.gov Identifier: NCT01494688).
Collapse
Affiliation(s)
- C A Gomez-Roca
- Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse.
| | - A Italiano
- Department of Medical Oncology, Institut Bergonié, Bordeaux.
| | - C Le Tourneau
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud; INSERM U900 Research Unit, Saint-Cloud; Paris-Saclay University, Paris
| | - P A Cassier
- Department of Medicine, Centre Léon Bérard, Lyon, France
| | - M Toulmonde
- Department of Medical Oncology, Institut Bergonié, Bordeaux
| | - S P D'Angelo
- Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, USA
| | - M Campone
- ICO René Gauducheau, Saint-Herblain, France
| | - K L Weber
- Department of Orthopedic Oncology, Penn Medicine, Pennsylvania, USA
| | - D Loirat
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud
| | - M A Cannarile
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - A-M Jegg
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - C Ries
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - R Christen
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - G Meneses-Lorente
- Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn Garden City
| | - W Jacob
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - I Klaman
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - C-H Ooi
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - C Watson
- A4P Consulting Ltd, Sandwich, UK
| | - K Wonde
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - B Reis
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - F Michielin
- Licensing and Early Development (LEAD) Safety Science, Roche Innovation Center Basel, Basel, Switzerland
| | - D Rüttinger
- Roche Innovation Center Munich, Roche Pharmaceutical Research and Early Development, Penzberg, Germany
| | - J-P Delord
- Department of Drug Development and Innovation, Institut Curie, Paris & Saint-Cloud
| | - J-Y Blay
- Department of Medicine & Clinical Research Unit, Institut Claudius Regaud/Institut Universitaire du Cancer de Toulouse (IUCT-Oncopole), Toulouse
| |
Collapse
|
15
|
Cejalvo JM, Jacob W, Fleitas Kanonnikoff T, Felip E, Navarro Mendivil A, Martinez Garcia M, Taus Garcia A, Leighl N, Lassen U, Mau-Soerensen M, Adessi C, Michielin F, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open 2019; 4:e000532. [PMID: 31423336 PMCID: PMC6678014 DOI: 10.1136/esmoopen-2019-000532] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2019] [Revised: 05/27/2019] [Accepted: 05/29/2019] [Indexed: 12/24/2022] Open
Abstract
Purpose This study investigated the safety and clinical activity of lumretuzumab, a humanised antihuman epidermal growth factor receptor 3 (HER3) monoclonal antibody, in combination with carboplatin and paclitaxel in first-line treatment of patients with squamous non-small cell lung cancer (sqNSCLC). HER3 ligand heregulin and HER3 protein expression were evaluated as potential biomarkers of clinical activity. Patients and methods This open-label, phase Ib/II study enrolled patients receiving lumretuzumab at 800 mg (flat) in combination with carboplatin (area under the curve (AUC) 6 mg/mL×min) and paclitaxel (200 mg/m2) administered intravenously on a every 3-week schedule. Adverse event (AE) rates and tumour responses were determined. Heregulin messenger RNA (mRNA) and HER3 protein expression were investigated in archival tumour biopsies. Results Altogether, 12 patients received lumretuzumab in combination with carboplatin and paclitaxel. The most frequent AEs were gastrointestinal, haematological and nervous system toxicities, which were generally mild and manageable. Partial responses were observed in 3 of 12 patients lasting 81, 177 and 207 days. All responses were achieved in tumours expressing higher heregulin mRNA levels. Conclusion Lumretuzumab in combination with carboplatin and paclitaxel was well tolerated. Objective responses were enriched in tumours expressing higher heregulin mRNA levels.
Collapse
Affiliation(s)
- Juan-Miguel Cejalvo
- Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain
| | - Wolfgang Jacob
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Tania Fleitas Kanonnikoff
- Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain
| | - Enriqueta Felip
- Department of Medical Oncology, University Hospital Vall d'Hebron, Barcelona, Spain
| | | | | | | | - Natasha Leighl
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Ulrik Lassen
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| | | | - Celine Adessi
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Francesca Michielin
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Ian James
- A4PConsulting Ltd, Sandwich, United Kingdom
| | - Maurizio Ceppi
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Max Hasmann
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Andrés Cervantes
- Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
16
|
Kim HS, Han JY, Shin DH, Lim KY, Lee GK, Kim JY, Jacob W, Ceppi M, Weisser M, James I. EGFR and HER3 signaling blockade in invasive mucinous lung adenocarcinoma harboring an NRG1 fusion. Lung Cancer 2018; 124:71-75. [DOI: 10.1016/j.lungcan.2018.07.026] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Revised: 07/19/2018] [Accepted: 07/19/2018] [Indexed: 12/21/2022]
|
17
|
Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortés J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Levy C, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, Racek T, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Invest New Drugs 2018; 36:848-859. [PMID: 29349598 PMCID: PMC6153514 DOI: 10.1007/s10637-018-0562-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2017] [Accepted: 01/10/2018] [Indexed: 01/03/2023]
Abstract
Purpose To investigate the safety and clinical activity of comprehensive human epidermal growth factor receptor (HER) family receptor inhibition using lumretuzumab (anti-HER3) and pertuzumab (anti-HER2) in combination with paclitaxel in patients with metastatic breast cancer (MBC). Methods This phase Ib study enrolled 35 MBC patients (first line or higher) with HER3-positive and HER2-low (immunohistochemistry 1+ to 2+ and in-situ hybridization negative) tumors. Patients received lumretuzumab (1000 mg in Cohort 1; 500 mg in Cohorts 2 and 3) plus pertuzumab (840 mg loading dose [LD] followed by 420 mg in Cohorts 1 and 2; 420 mg without LD in Cohort 3) every 3 weeks, plus paclitaxel (80 mg/m2 weekly in all cohorts). Patients in Cohort 3 received prophylactic loperamide treatment. Results Diarrhea grade 3 was a dose-limiting toxicity of Cohort 1 defining the maximum tolerated dose of lumretuzumab when given in combination with pertuzumab and paclitaxel at 500 mg every three weeks. Grade 3 diarrhea decreased from 50% (Cohort 2) to 30.8% (Cohort 3) with prophylactic loperamide administration and omission of the pertuzumab LD, nonetheless, all patients still experienced diarrhea. In first-line MBC patients, the objective response rate in Cohorts 2 and 3 was 55% and 38.5%, respectively. No relationship between HER2 and HER3 expression or somatic mutations and clinical response was observed. Conclusions Combination treatment with lumretuzumab, pertuzumab and paclitaxel was associated with a high incidence of diarrhea. Despite the efforts to alter dosing, the therapeutic window remained too narrow to warrant further clinical development. TRIAL REGISTRATION on ClinicalTrials.gov with the identifier NCT01918254 first registered on 3rd July 2013.
Collapse
MESH Headings
- Adult
- Aged
- Antibodies, Monoclonal, Humanized/administration & dosage
- Antibodies, Monoclonal, Humanized/adverse effects
- Antibodies, Monoclonal, Humanized/pharmacokinetics
- Antineoplastic Agents/administration & dosage
- Antineoplastic Agents/adverse effects
- Antineoplastic Agents/pharmacokinetics
- Antineoplastic Combined Chemotherapy Protocols/administration & dosage
- Antineoplastic Combined Chemotherapy Protocols/adverse effects
- Breast Neoplasms/drug therapy
- Breast Neoplasms/genetics
- Breast Neoplasms/metabolism
- Diarrhea/chemically induced
- Female
- Humans
- Hypokalemia/chemically induced
- Male
- Middle Aged
- Paclitaxel/administration & dosage
- Paclitaxel/adverse effects
- Polymorphism, Single Nucleotide
- Receptor, ErbB-2/antagonists & inhibitors
- Receptor, ErbB-2/genetics
- Receptor, ErbB-2/metabolism
- Receptor, ErbB-3/antagonists & inhibitors
- Receptor, ErbB-3/genetics
- Receptor, ErbB-3/metabolism
Collapse
Affiliation(s)
- Andreas Schneeweiss
- National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Tjoung-Won Park-Simon
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany
| | - Joan Albanell
- Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain
| | | | - Javier Cortés
- Ramon y Cajal University Hospital, Madrid, Spain
- Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - Marcus May
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany
| | - Christoph Schindler
- Department of Obstetrics and Gynecology, Division of Gynecological Oncology and Clinical Research Center, Hannover Medical School, Hannover, Germany
| | - Frederik Marmé
- National Center for Tumor Diseases, Heidelberg University Hospital, Heidelberg, Germany
| | - Juan Miguel Cejalvo
- Department of Medical Oncology, Biomedical Health Research Institute INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain
| | | | - Iria Gonzalez
- Department of Medical Oncology, Hospital del Mar, CIBERONC, Barcelona, Spain
| | - Jose Lopez-Martin
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - Anja Welt
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany
| | - Christelle Levy
- Departments of Clinical Research Unit and Medical Oncology, Centre François Baclesse, Caen, France
| | - Florence Joly
- Departments of Clinical Research Unit and Medical Oncology, Centre François Baclesse, Caen, France
| | - Francesca Michielin
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Wolfgang Jacob
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany.
| | - Céline Adessi
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Annie Moisan
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Georgina Meneses-Lorente
- Pharma Research and Early Development (pRED), Roche Innovation Center Welwyn, Welwyn Garden City, UK
| | - Tomas Racek
- Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | | | - Maurizio Ceppi
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Max Hasmann
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development (pRED), Roche Innovation Center Munich, Penzberg, Germany
| | - Andrés Cervantes
- Department of Medical Oncology, Biomedical Health Research Institute INCLIVA, University of Valencia, Valencia and CIBERONC, Institute of Health Carlos III, Madrid, Spain
| |
Collapse
|
18
|
Arredondo R, Oberkofler M, Schmid K, Schwarz-Selinger T, Jacob W, Neu R. SIESTA: A high current ion source for erosion and retention studies. Rev Sci Instrum 2018; 89:103501. [PMID: 30399784 DOI: 10.1063/1.5039156] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/07/2018] [Accepted: 09/08/2018] [Indexed: 06/08/2023]
Abstract
Second ion experiment for sputtering and TDS analysis is a high-current ion source for erosion and retention studies with focus on wall materials for fusion devices. The system is composed of a DuoPIGatron type ion source, three consecutive grids for ion extraction, acceleration and beam focusing, a differential pumping stage, a dipole magnet for mass filtering, a quadrupole doublet lens, a target chamber, a load-lock, and a chamber for thermal desorption spectrometry. The acceleration potential of the source can be varied between 500 V and 10 kV. The target chamber has a base pressure of 10-8 mbar and an operating pressure of 5 × 10-7 mbar. The target can be rotated to study angle-dependent effects and can be heated via electron-impact heating up to 1300 K for high temperature erosion and implantation studies. The target chamber is equipped with an in situ magnetic suspension balance. The operating parameters of the ion source were mapped to achieve the maximum ion current at the target for various gas species and accelerating potentials. The beam emittance for a D3 + ion beam was measured after deflection in the dipole magnet. This was used for ion beam simulations, which were instrumental for the design of the quadrupole lenses. If the quadrupole doublet is used, the ion flux to the target is increased by up to a factor of 4. Additionally, the relative population of neutral particles present in the beam at the target was quantified and is equal to 0.8% when averaged over the measurement positions. The typical beam footprint at the target under normal incidence has an area of 0.5 cm2. The ion current reaching the target increases with the accelerating potential. Due to this effect, the ion flux density at the target in the low-ion-impact-energy range can be increased by operating the source at a higher extraction potential and by applying a (decelerating) potential to the target. Ion impact energies as low as 200 eV/D are achieved this way with a D3 + current of 100 μA when focusing the beam with the quadrupole doublet lens, equating to a D particle flux density of 3.7 × 1019 m-2 s-1. At ion impact energies of 2 keV/D, the maximum achievable flux density with D3 + is 6 × 1019 D m-2 s-1. Experimental determination of sputter yields was performed via ex situ weight loss measurement for bulk Au samples, showing reasonably good agreement with simulations and experimental data from the literature.
Collapse
Affiliation(s)
- R Arredondo
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| | - M Oberkofler
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| | - K Schmid
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| | - T Schwarz-Selinger
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| | - W Jacob
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| | - R Neu
- Max-Planck-Institut für Plasmaphysik, Boltzmannstrasse 2, Garching D-85748, Germany
| |
Collapse
|
19
|
Sugiyama K, Balden M, Elgeti S, Höschen T, Oberkofler M, Roth J, Jacob W. Erosion of EUROFER steel by mass-selected deuterium ion bombardment. Nuclear Materials and Energy 2018. [DOI: 10.1016/j.nme.2018.05.021] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
20
|
Jacob W, James I, Hasmann M, Weisser M. Clinical development of HER3-targeting monoclonal antibodies: Perils and progress. Cancer Treat Rev 2018; 68:111-123. [PMID: 29944978 DOI: 10.1016/j.ctrv.2018.06.011] [Citation(s) in RCA: 34] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 06/14/2018] [Accepted: 06/15/2018] [Indexed: 12/16/2022]
Abstract
The human epidermal growth factor receptor (HER) family consists of four transmembrane receptor tyrosine kinases: epidermal growth factor receptor (EGFR), HER2, HER3, and HER4. They are part of a complex signalling network and stimulate intracellular pathways regulating cell growth and differentiation. So far, monoclonal antibodies (mAbs) and small molecule tyrosine kinase inhibitors targeting EGFR and HER2 have been developed and approved. Recently, focus has turned to HER3 as it may play an important role in resistance to EGFR- and HER2-targeting therapies. HER3-targeting agents have been undergoing clinical evaluation for the last 10 years and currently thirteen mAbs are in phase 1 or 2 clinical studies. Single agent activity has proven to be limited, however, the tolerability was favourable. Thus, combinations of HER3-binding mAbs with other HER-targeting therapies or chemotherapies have been pursued in various solid tumor entities. Data indicate that the HER3-binding ligand heregulin may serve as a response prediction marker for HER3-targeting therapy. Within this review the current status of clinical development of HER3-targeting compounds is described.
Collapse
Affiliation(s)
- Wolfgang Jacob
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
| | - Ian James
- A4P Consulting Ltd, Discovery Park, Sandwich, UK
| | - Max Hasmann
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| |
Collapse
|
21
|
Zhao M, Jacob W, Gao L, Manhard A, Dürbeck T, Zhou Z. Deuterium retention behavior of pure and Y2O3-doped tungsten investigated by nuclear reaction analysis and thermal desorption spectroscopy. Nuclear Materials and Energy 2018. [DOI: 10.1016/j.nme.2018.05.016] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
22
|
Moisan A, Michielin F, Jacob W, Kronenberg S, Wilson S, Avignon B, Gérard R, Benmansour F, McIntyre C, Meneses-Lorente G, Hasmann M, Schneeweiss A, Weisser M, Adessi C. Mechanistic Investigations of Diarrhea Toxicity Induced by Anti-HER2/3 Combination Therapy. Mol Cancer Ther 2018; 17:1464-1474. [DOI: 10.1158/1535-7163.mct-17-1268] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2017] [Revised: 02/23/2018] [Accepted: 04/06/2018] [Indexed: 11/16/2022]
|
23
|
Jacob W. Basis-Dokumentation in der Pathologie. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1636267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Die Vielfältigkeit der Aufgaben einer Basisdokumentation in der Pathologie bedarf geeigneter Methoden, mit deren Hilfe eine genügende Verläßlichkeit der Dokumentation morphologischer Befunde im Rahmen der Eingangshistologie und Sektionsdiagnostik erreicht werden kann. Die Methode der »halbautomatischen Verschlüsselung«, das sog. »over-cross«-Verfahren, erlaubt eine uneingeschränkte Dokumentation aller in der Pathoanatomie zu dokumentierenden Befunde mit einem sehr reduzierten Arbeitsaufwand, zugleich einer technisch relativ einfachen Handhabung, welche zudem Fehlermöglichkeiten wesentlich einschränkt. Umständliches Verschlüsseln »von Hand« entfällt, die Fehlerkontrolle der Daten ist sehr vereinfacht. Das »over-cross«-Verfahren erlaubt eine maschinelle Herstellung der Lochkarten sowie die Verwendung eines Dualzahlenschlüssels, welcher die Kapazität der einzelnen Lochkarte erheblich steigert. Sortier- und Selektiervorgänge lassen sich wesentlich beschleunigen.
Collapse
|
24
|
Jacob W. Zur Methode der maschinellen Dokumentation histologischer Befunde in der Pathologie. Methods Inf Med 2018. [DOI: 10.1055/s-0038-1636246] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Verf. beschreibt das von ihm für die routinemäßige Erfassung der histologischen Befunde eines großen pathologischen Instituts entwickelte Dokumentationssystem, das bei Verwendung eines bis zu 5stelligen alphabetischen Kurzschlüssels für die diagnostischen Begriffe den Vorteil der Lesbarkeit der Karten bietet. Sortiert nach dem Namen des Patienten dienen die Karten als Suchkartei und für die Beantwortung von Anfragen; ein zweiter Kartensatz dient der wissenschaftlichen Auswertung der Befunde. Die Bearbeitung des Materials erfolgt mittels eines Maul-Selektors AS 12, der die gleichzeitige Selektion von bis zu 12spaltigen Begriffen gestattet.
Collapse
|
25
|
Spitaels R, Jacob W, Janssens F, Schurmans P, Vanmoerkerke L, Walgraeve D, Coenegrachts JL. Thoracic aortic aneurysm complicated by secondary aortoesophageal fistula after thoracic endovascular aortic repair : a case report. Acta Gastroenterol Belg 2017; 80:527-525. [PMID: 29560649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
This is a case report of a patient with a thoracic aortic aneurysm (TAA) presenting with dysphagia and weight loss as primary symptoms. She was treated via thoracic endovascular aortic repair (TEVAR). The procedure was complicated with a secondary aortoesophageal fistula (AEF) for which open surgical repair of the esophageal defect was done. Long term (i.e. more than 30 days) antibiotics were given. The recovery was uneventful.
Collapse
Affiliation(s)
- R Spitaels
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | - W Jacob
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | - F Janssens
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | - P Schurmans
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | - L Vanmoerkerke
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | - D Walgraeve
- Dept. of Gastroenterology, Jessa Ziekenhuis, Hasselt, Belgium
| | | |
Collapse
|
26
|
Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE. 89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors. Clin Cancer Res 2017; 23:6128-6137. [PMID: 28733442 DOI: 10.1158/1078-0432.ccr-17-0311] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2017] [Revised: 05/30/2017] [Accepted: 07/18/2017] [Indexed: 01/24/2023]
Abstract
Purpose: We evaluated biodistribution and tumor targeting of 89Zr-lumretuzumab before and during treatment with lumretuzumab, a human epidermal growth factor receptor 3 (HER3)-targeting monoclonal antibody.Experimental Design: Twenty patients with histologically confirmed HER3-expressing tumors received 89Zr-lumretuzumab and underwent positron emission tomography (PET). In part A, 89Zr-lumretuzumab was given with additional, escalating doses of unlabeled lumretuzumab, and scans were performed 2, 4, and 7 days after injection to determine optimal imaging conditions. In part B, patients were scanned following tracer injection before (baseline) and after a pharmacodynamic (PD)-active lumretuzumab dose for saturation analysis. HER3 expression was determined immunohistochemically in skin biopsies. Tracer uptake was calculated as standardized uptake value (SUV).Results: Optimal PET conditions were found to be 4 and 7 days after administration of 89Zr-lumretuzumab with 100-mg unlabeled lumretuzumab. At baseline using 100-mg unlabeled lumretuzumab, the tumor SUVmax was 3.4 (±1.9) at 4 days after injection. SUVmean values for normal blood, liver, lung, and brain tissues were 4.9, 6.4, 0.9 and 0.2, respectively. Saturation analysis (n = 7) showed that 4 days after lumretuzumab administration, tumor uptake decreased by 11.9% (±8.2), 10.0% (±16.5), and 24.6% (±20.9) at PD-active doses of 400, 800, and 1,600 mg, respectively, when compared with baseline. Membranous HER3 was completely downregulated in paired skin biopsies already at and above 400-mg lumretuzumab.Conclusions: PET imaging showed biodistribution and tumor-specific 89Zr-lumretuzumab uptake. Although, PD-active lumretuzumab doses decreased 89Zr-lumretuzumab uptake, there was no clear evidence of tumor saturation by PET imaging as the tumor SUV did not plateau with increasing doses. Clin Cancer Res; 23(20); 6128-37. ©2017 AACR.
Collapse
Affiliation(s)
- Frederike Bensch
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Laetitia E Lamberts
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Michaël M Smeenk
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Annelies Jorritsma-Smit
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Marjolijn N Lub-de Hooge
- Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands.,Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, the Netherlands
| | | | - Johan R de Jong
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Jourik A Gietema
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Carolien P Schröder
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Marlene Thomas
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Wolfgang Jacob
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Keelara Abiraj
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Celine Adessi
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | | | - Ian James
- A4P Consulting Ltd, Sandwich, United Kingdom
| | - Martin Weisser
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Adrienne H Brouwers
- Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, the Netherlands
| | - Elisabeth G E de Vries
- Department of Medical Oncology, University of Groningen, University Medical Center Groningen, the Netherlands.
| |
Collapse
|
27
|
Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, Rüttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer 2017; 5:53. [PMID: 28716061 PMCID: PMC5514481 DOI: 10.1186/s40425-017-0257-y] [Citation(s) in RCA: 637] [Impact Index Per Article: 91.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2017] [Accepted: 06/05/2017] [Indexed: 12/26/2022] Open
Abstract
The tumor-permissive and immunosuppressive characteristics of tumor-associated macrophages (TAM) have fueled interest in therapeutically targeting these cells. In this context, the colony-stimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches targeting either the ligands or the receptor are currently in clinical development. Emerging data on the tolerability of CSF1/CSF1R-targeting agents suggest a favorable safety profile, making them attractive combination partners for both standard treatment modalities and immunotherapeutic agents. The specificity of these agents and their potent blocking activity has been substantiated by impressive response rates in diffuse-type tenosynovial giant cell tumors, a benign connective tissue disorder driven by CSF1 in an autocrine fashion. In the malignant disease setting, data on the clinical activity of immunotherapy combinations with CSF1/CSF1R-targeting agents are pending. As our knowledge of macrophage biology expands, it becomes apparent that the complex phenotypic and functional properties of macrophages are heavily influenced by a continuum of survival, differentiation, recruitment, and polarization signals within their specific tissue environment. Thus, the role of macrophages in regulating tumorigenesis and the impact of depleting and/or reprogramming TAM as therapeutic approaches for cancer patients may vary greatly depending on organ-specific characteristics of these cells. We review the currently available clinical safety and efficacy data with CSF1/CSF1R-targeting agents and provide a comprehensive overview of ongoing clinical studies. Furthermore, we discuss the local tissue macrophage and tumor-type specificities and their potential impact on CSF1/CSF1R-targeting treatment strategies for the future.
Collapse
Affiliation(s)
- Michael A. Cannarile
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| | - Martin Weisser
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| | - Wolfgang Jacob
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| | - Anna-Maria Jegg
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| | - Carola H. Ries
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| | - Dominik Rüttinger
- Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, Penzberg, 82377 Germany
| |
Collapse
|
28
|
Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, Han JY, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clin Cancer Res 2017; 23:5406-5415. [PMID: 28600476 DOI: 10.1158/1078-0432.ccr-17-0812] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2017] [Revised: 05/03/2017] [Accepted: 06/05/2017] [Indexed: 11/16/2022]
Abstract
Purpose: This study investigated the safety, clinical activity, and target-associated biomarkers of lumretuzumab, a humanized, glycoengineered, anti-HER3 monoclonal antibody (mAb), in combination with the EGFR-blocking agents erlotinib or cetuximab in patients with advanced HER3-positive carcinomas.Experimental Design: The study included two parts: dose escalation and dose extension phases with lumretuzumab in combination with either cetuximab or erlotinib, respectively. In both parts, patients received lumretuzumab doses from 400 to 2,000 mg plus cetuximab or erlotinib according to standard posology, respectively. The effect of HRG mRNA and HER3 mRNA and protein expression were investigated in a dedicated extension cohort of squamous non-small cell lung cancer (sqNSCLC) patients treated with lumretuzumab and erlotinib.Results: Altogether, 120 patients were treated. One dose-limiting toxicity (DLT) in the cetuximab part and two DLTs in the erlotinib part were reported. The most frequent adverse events were gastrointestinal and skin toxicities, which were manageable. The objective response rate (ORR) was 6.1% in the cetuximab part and 4.2% in the erlotinib part. In the sqNSCLC extension cohort of the erlotinib part, higher tumor HRG and HER3 mRNA levels were associated with a numerically higher disease control rate but not ORR.Conclusions: The toxicity profile of lumretuzumab in combination with cetuximab and erlotinib was manageable, but only modest clinical activity was observed across tumor types. In the sqNSCLC cohort, there was no evidence of meaningful clinical benefit despite enriching for tumors with higher HRG mRNA expression levels. Clin Cancer Res; 23(18); 5406-15. ©2017 AACR.
Collapse
Affiliation(s)
- Didier Meulendijks
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | - Wolfgang Jacob
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany.
| | - Emile E Voest
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands
| | | | | | - Alvaro Taus
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
| | - Tania Fleitas
- Department of Medical Oncology, CIBERONC, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Andres Cervantes
- Department of Medical Oncology, CIBERONC, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Martijn P Lolkema
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.,Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | - Marlies H G Langenberg
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Maja J De Jonge
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | - Stefan Sleijfer
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | - Ji-Youn Han
- Center for Lung Cancer, National Cancer Center, Goyang, South Korea
| | - Antonio Calles
- START-Madrid, Centro Integral Oncológico Clara Campal, Madrid, Spain
| | - Enriqueta Felip
- Medical Oncology Department, Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | - Sang-We Kim
- Department of Oncology, Asan Medical Center, Seoul, South Korea
| | - Jan H M Schellens
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.,Utrecht Institute for Pharmaceutical Sciences (UIPS), University Utrecht, Utrecht, the Netherlands
| | - Sabine Wilson
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Marlene Thomas
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Maurizio Ceppi
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | | | - Ian James
- A4P Consulting Ltd, Discovery Park, Sandwich, United Kingdom
| | - Suzana Vega-Harring
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Rajiv Dua
- Roche Molecular Systems Inc., Pleasanton, California
| | | | - Lori Steiner
- Roche Molecular Systems Inc., Pleasanton, California
| | - Celine Adessi
- Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland
| | - Francesca Michielin
- Pharma Research and Early Development, Roche Innovation Center, Basel, Basel, Switzerland
| | - Birgit Bossenmaier
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Martin Weisser
- Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany
| | - Ulrik N Lassen
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
29
|
Collins D, Jacob W, Cejalvo JM, Ceppi M, James I, Hasmann M, Crown J, Cervantes A, Weisser M, Bossenmaier B. Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer. PLoS One 2017; 12:e0177331. [PMID: 28493933 PMCID: PMC5426757 DOI: 10.1371/journal.pone.0177331] [Citation(s) in RCA: 37] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2017] [Accepted: 04/26/2017] [Indexed: 11/24/2022] Open
Abstract
Bidirectional cross talk between members of the human epidermal growth factor family of receptors (HER) and the estrogen receptor (ER) is believed to underlie resistance mechanisms that develop in response to treatment with anti-HER agents and endocrine therapy. We investigated the interaction between HER2, HER3 and the ER in vitro using human embryonic kidney cells transfected with human HER2, HER3, and ERα. We also investigated the additive efficacy of combination regimens consisting of anti-HER3 (lumretuzumab), anti-HER2 (pertuzumab), and endocrine (fulvestrant) therapy in vivo. Our data show that both HER2 and HER3 can directly complex with the ER and can mediate phosphorylation of the ER. Phosphorylation of the ER was only observed in cells that expressed both HER2 and ERα or in heregulin-stimulated cells that expressed both HER3 and ERα. Using a mouse xenograft model of ER+/HER2-low (HER2 immunohistochemistry 1+ or 2+ without gene amplification) human breast cancer we show that the combination of lumretuzumab and pertuzumab is highly efficacious and induces long-lasting tumor regression in vivo and adding endocrine therapy (fulvestrant) to this combination further improved efficacy. In addition, a prolonged clinical response was observed with the combination of lumretuzumab and pertuzumab in a patient with ER+/HER2-low breast cancer who had failed endocrine therapy. These preclinical data confirm that direct cross talk exists between HER2/HER3 and ER which may explain the resistance mechanisms to endocrine therapy and monoclonal antibodies that target HER2 and HER3. Our data also indicate that the triplet of anti-HER2, anti-HER3, and endocrine therapy might be an efficacious combination for treating patients with ER+/HER2-low breast cancer, which is an area of significant unmet medical need.
Collapse
Affiliation(s)
- Denis Collins
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- * E-mail: (DC); (MW)
| | | | - Juan Miguel Cejalvo
- Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | | | - Ian James
- A4P Consulting Ltd, Sandwich, United Kingdom
| | - Max Hasmann
- Roche Innovation Center Munich, Penzberg, Germany
| | - John Crown
- National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
- Department of Medical Oncology, St. Vincent's University Hospital, Dublin, Ireland
| | - Andrés Cervantes
- Department of Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Martin Weisser
- Roche Innovation Center Munich, Penzberg, Germany
- * E-mail: (DC); (MW)
| | | |
Collapse
|
30
|
Schneeweiss A, Park-Simon TW, Albanell J, Lassen U, Cortes J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Abstract P6-11-13: Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p6-11-13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Inhibition of HER2 and HER3 heterodimerisation is a novel treatment concept in HER2-”low” expressing breast cancer (BC). Lumretuzumab, a glycoengineered monoclonal anti-HER3 antibody, in combination with pertuzumab has demonstrated synergistic anti-tumor activity in preclinical HER2–low expressing preclinical BC models.
Methods: This open-label, multicenter phase I study selectively enrolled metastatic BC patients (pts) expressing HER3 protein and low levels of HER2 (defined as IHC 1+ and 2+ and ISH-negative) in a formalin-fixed paraffin-embedded pretreatment tumor biopsy sample. Eligible pts were treated with a combination of paclitaxel (PA) qw plus lumretuzumab (L) and pertuzumab (P) q3w in three dose cohorts. The safety, antitumor activity and tumor biomarkers including protein expression (IHC, MS) and mutational data (NGS) in association with clinical activity were evaluated.
Results: Overall, 35 pts were included in this study. The median age was 60 (range: 33 to 77) years. The median number of prior treatments for metastatic disease ranged from 0 to 5 with 23 pts (65.7%) without prior chemotherapy for metastatic disease. Cohort 1 was treated with PA at 80 mg/m2, L at 1000 mg and P at 840 mg for Cycle 1 followed by 420 mg for the following cycles. This cohort was stopped after two pts both experienced grade 3 diarrhea within the first treatment cycle which was considered a dose-limiting toxicity (DLT). For Cohort 2 the dose of L was reduced to 500 mg based on PK modelling and simulation data. No DLTs were seen for the first 6 pts. A total of 20 pts were recruited with an objective response rate (ORR) and disease control rate (DCR) of 30% and 75%, respectively, and 56% and 78%, respectively, for 1st-line pts (n=9) in this cohort. Diarrhea (≥G3) and hypokalemia (≥G3) occurred in 50% and 55% of pts, respectively, and all pts experienced chronic diarrhea throughout the course of treatment. For Cohort 3 the dose of L was maintained at 500 mg, PA at 80 mg/m2, and P was administered at 420 mg at all cycles. In addition, a prophylactic loperamide regimen was introduced. Altogether, 13 pts - all 1st-line for metastatic disease - were treated. No DLTs were seen for the first 6 pts. Diarrhea (≥G3) and hypokalemia (≥G3) were reduced to 31% and 15%, respectively, but chronic diarrhea was still observed throughout the treatment in all pts. The ORR and DCR were 31% and 77%, respectively. Preliminary mechanistic safety experiments revealed HER2/HER3-dependent chloride channels in the intestine as likely cause of diarrhea. Biomarker data will be presented along with updated clinical and safety data.
Conclusions: The combination of L, P and PA was associated with high rates of persistent diarrhea. Dose modifications and prophylactic anti-diarrheal medication led to significantly reduced diarrhea intensity but did not change the incidence and persistence of diarrhea overall. Despite encouraging clinical activity especially in 1st line pts, the therapeutic window of this combination is too low to warrant further clinical development.
Citation Format: Schneeweiss A, Park-Simon T-W, Albanell J, Lassen U, Cortes J, Dieras V, May M, Schindler C, Marmé F, Cejalvo JM, Martinez-Garcia M, Gonzalez I, Lopez-Martin J, Welt A, Joly F, Michielin F, Jacob W, Adessi C, Moisan A, Meneses-Lorente G, James I, Ceppi M, Hasmann M, Weisser M, Cervantes A. Phase Ib study evaluating the safety and clinical activity of lumretuzumab combined with pertuzumab and paclitaxel in HER2-low metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-11-13.
Collapse
Affiliation(s)
- A Schneeweiss
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - T-W Park-Simon
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - J Albanell
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - U Lassen
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - J Cortes
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - V Dieras
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - M May
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - C Schindler
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - F Marmé
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - JM Cejalvo
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - M Martinez-Garcia
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - I Gonzalez
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - J Lopez-Martin
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - A Welt
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - F Joly
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - F Michielin
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - W Jacob
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - C Adessi
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - A Moisan
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - G Meneses-Lorente
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - I James
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - M Ceppi
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - M Hasmann
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - M Weisser
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| | - A Cervantes
- National Center for Tumor Diseases, University Hospital, Heidelberg, Germany; 2Clinics of Obstetrics and Gynecology, Hannover Medical School, Hannover, Germany; Hospital del Mar, Barcelona, Spain; Rigshospitalet, Copenhagen, Denmark; Vall d'Hebron Institute of Oncology, Barcelona, Spain; Institut Curie, Paris, France; Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain; Hospital Universitario 12 de Octubre, Madrid, Spain; West German Cancer Centre, University Hospital Essen, Essen, Germany; Center François Baclesse, Caen, France; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland; Roche Pharmaceutical Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; Pharma Research and Early Development, Clinical Pharmacology, Roche Innovation Center Welwyn, Welwyn Garden City, United Kingdom; A4P Consulting Ltd, Sandwich, United Kingdom
| |
Collapse
|
31
|
|
32
|
Meulendijks D, Lassen U, Cervantes A, Han JY, Calles A, Felip E, Kim SW, Schellens J, Taus A, Sorensen M, Fleitas T, Bossenmaier B, Michielin F, Adessi C, Meneses-Lorente G, Ceppi M, James I, Jacob W, Weisser M, Martinez-Garcia M. Impact of tumor heregulin mRNA expression on outcome of patients with advanced/metastatic squamous NSCLC treated with lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with erlotinib. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Cejalvo J, Fleitas T, Felip E, Mendivil AN, Martinez-Garcia M, Taus A, Leighl N, Lassen U, Soerensen MM, Adessi C, Michielin F, Jacob W, James I, Ceppi M, Weisser M, Cervantes A. A phase Ib study of lumretuzumab, a glycoengineered monoclonal antibody targeting HER3, in combination with carboplatin and paclitaxel as 1st-line treatment in patients with squamous non-small cell lung cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw368.15] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
34
|
Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AG, de Jong JR, Gietema JA, Schroder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, De Vries E. 89Zr-lumretuzumab PET imaging before and during HER3 antibody lumretuzumab treatment of solid tumor patients. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.11555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Marlene Thomas
- Research and Early Development, Roche Pharma, Penzberg, Germany
| | - Wolfgang Jacob
- Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Penzberg, Germany
| | - Keelara Abiraj
- Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland
| | - Celine Adessi
- Roche Pharma Research and Early Development (pRED), Roche Innovation Center Basel, Basel, Switzerland
| | - Georgina Meneses-Lorente
- Roche Innovation Center Welwyn, Roche Pharmaceutical Research and Early Development, Welwyn, United Kingdom
| | - Ian James
- A4P Consulting Ltd, Sandwich, United Kingdom
| | - Martin Weisser
- Roche Pharma Research and Early Development (pRED), Roche Innovation Center Penzberg, Penzberg, Germany
| | | | | |
Collapse
|
35
|
Sugiyama K, Porosnicu C, Jacob W, Jepu I, Lungu C. Investigation of deuterium retention in/desorption from beryllium-containing mixed layers. Nuclear Materials and Energy 2016. [DOI: 10.1016/j.nme.2015.08.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
36
|
Meulendijks D, Jacob W, Martinez-Garcia M, Taus A, Lolkema MP, Voest EE, Langenberg MHG, Fleitas Kanonnikoff T, Cervantes A, De Jonge MJ, Sleijfer S, Soerensen MM, Thomas M, Ceppi M, Meneses-Lorente G, James I, Adessi C, Michielin F, Abiraj K, Bossenmaier B, Schellens JHM, Weisser M, Lassen UN. First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors. Clin Cancer Res 2015; 22:877-85. [PMID: 26463709 DOI: 10.1158/1078-0432.ccr-15-1683] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 09/23/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE A first-in-human phase I study was conducted to characterize safety, efficacy, and pharmacokinetic (PK) and pharmacodynamic (PD) properties of lumretuzumab, a humanized and glycoengineered anti-HER3 monoclonal antibody, in patients with advanced cancer. EXPERIMENTAL DESIGN Twenty-five patients with histologically confirmed HER3-expressing tumors received lumretuzumab (100, 200, 400, 800, 1,600, and 2,000 mg) every two weeks (q2w) in 3+3 dose-escalation phase. In addition, 22 patients were enrolled into an extension cohort at 2,000 mg q2w. RESULTS There were no dose-limiting toxicities. Common adverse events (any grade) included diarrhea (22 patients, 46.8%), fatigue (21 patients, 44.7%), decreased appetite (15 patients, 31.9%), infusion-related reactions (13 patients, 27.7%), and constipation (10 patients, 21.3%). The peak concentration (Cmax) and area under the concentration-time curve up to the last measurable concentration (AUClast) of lumretuzumab increased more than dose proportionally from 100 mg up to 400 mg. Linear PK was observed with doses ≥ 400 mg q2w indicating target-mediated drug disposition saturation. Downregulation of HER3 membranous protein was observed in on-treatment tumor biopsies from 200 mg, and was maximal at and above 400 mg. An ex vivo assay demonstrated increased activation potential of peripheral NK lymphocytes with lumretuzumab compared with a non-glycoengineered anti-HER3 antibody. Ten patients (21.3%) had stable disease and remained on study at a median of 111 days (range, 80-225 days). CONCLUSIONS Lumretuzumab was well tolerated and showed evidence of clinical activity. Linear serum PK properties and plateauing of PD effects in serial tumor biopsies indicate optimal biologically active doses of lumretuzumab from 400 mg onwards.
Collapse
Affiliation(s)
- Didier Meulendijks
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Wolfgang Jacob
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany.
| | | | - Alvaro Taus
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
| | - Martijn P Lolkema
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands. Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | - Emile E Voest
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Marlies H G Langenberg
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands
| | - Tania Fleitas Kanonnikoff
- Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Andres Cervantes
- Department of Hematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | - Maja J De Jonge
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | - Stefan Sleijfer
- Department of Medical Oncology, Erasmus Medical Center Cancer Institute and Cancer Genomics, Rotterdam, the Netherlands
| | | | - Marlene Thomas
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany
| | - Maurizio Ceppi
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany
| | | | - Ian James
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany
| | - Celine Adessi
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Francesca Michielin
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Keelara Abiraj
- Pharma Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
| | - Birgit Bossenmaier
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany
| | - Jan H M Schellens
- Department of Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - Martin Weisser
- Pharma Research and Early Development, Roche Innovation Center Penzberg, Penzberg, Germany
| | - Ulrik N Lassen
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
37
|
Lassen U, Ruiperez AC, Fleitas T, Meulendijks D, Schellens J, Lolkemar M, De Jonge M, Sleijfer S, Mau-Soerensen M, Taus A, Adessi C, Keelara A, Michielin F, Bossenmaier B, Meneses-Lorente G, James I, Jacob W, Weisser M, Martinez-Garcia M. Phase Ib Trial Trial of Rg7116, a Glycoengineered Monoclonal Antibody Targeting Her3, in Combination with Cetuximab or Erlotinib in Patients with Advanced/Metastatic Tumors of Epithelial Cell Origin Expressing Her3 Protein. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu331.4] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Bensch F, Lamberts LE, Lub-de Hooge MN, Terwisscha van Scheltinga AG, de Jong JR, Gietema JA, Schroder CP, Smeenk MM, Jacob W, Abiraj K, Wolf M, Adessi C, Meneses-Lorente G, Zajac M, Weisser M, Brouwers AH, De Vries E. Phase I imaging study of the HER3 antibody RG7116 using 89Zr-RG7116-PET in patients with metastatic or locally advanced HER3-positive solid tumors. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.11095] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Frederike Bensch
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Laetitia E. Lamberts
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Marjolijn N. Lub-de Hooge
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, Netherlands
| | | | - Johan R. de Jong
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands
| | - Jourik A. Gietema
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Carolien P. Schroder
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Michiel M. Smeenk
- Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands
| | - Wolfgang Jacob
- Roche Pharma Research and Early Development (pRED), Penzberg, Germany
| | - Keelara Abiraj
- Roche Pharma Research and Early Development (pRED), Basel, Switzerland
| | - Michaela Wolf
- Roche Pharma Research and Early Development (pRED), Basel, Switzerland
| | - Celine Adessi
- Roche Pharma Research and Early Development (pRED), Basel, Switzerland
| | | | | | - Martin Weisser
- Roche Pharma Research and Early Development (pRED), Penzberg, Germany
| | - Adrienne H. Brouwers
- Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, Groningen, Netherlands
| | | |
Collapse
|
39
|
Meulendijks D, Lolkema MPJK, Voest EE, De Jonge MJ, Sleijfer S, Schellens JHM, Fleitas T, Cervantes-Ruiperez A, Martinez-Garcia M, Taus A, Soerensen MM, Thomas M, Meneses-Lorente G, Adessi C, Di Scala L, Keelara A, Jacob W, Weisser M, Lassen UN. A first-in-human trial of RG7116, a glycoengineered monoclonal antibody targeting HER3, in patients with advanced/metastatic tumors of epithelial cell origin expressing HER3 protein. J Clin Oncol 2013. [DOI: 10.1200/jco.2013.31.15_suppl.2522] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2522 Background: The Human Epidermal Growth Factor Receptor 3 (HER3) is a key heterodimerization partner for other HER family members thereby acting as a downstream signal amplifier. This is a first in human study evaluating the safety of RG7116, a humanized anti-HER3 monoclonal antibody with potent HER3 signal inhibition. Due to a glycoengineered Fc-part this antibody displays enhanced antibody-dependent cellular cytotoxicity as compared to conventional antibodies. Methods: Patients (pts) with advanced or metastatic carcinomas with centrally confirmed HER3 protein expression were included. A “3+3” dose escalation design was performed starting at 100 mg flat dosing in a q2w regimen. In addition to single agent RG7116 (Part A), RG7116 plus cetuximab (Part B) and RG7116 plus erlotinib (Part C) combinations are evaluated. The results of Part A are presented. Results: Twenty-five pts have been enrolled in 6 cohorts (100 to 2000 mg). No DLTs were observed. Pts had a median (range) of 3 (2 to 6) prior chemotherapy lines. Nine infusion-related reactions (IRRs) Gr 1 to 3 occurred in 7 pts. Three drug-related AEs Gr 3 were reported, 1 IRR, 1 GGT increase, and 1 neutropenia. Only 1 patient was tested positive for human anti human antibodies (HAHA). The PK of RG7116 was non-linear from 100 mg up to 400 mg, possibly as a result of target-mediated drug disposition. Both Cmax and AUC showed a greater than doseEproportional increase over the same dose range, accompanied by a decline in total clearance. Dose proportionality was observed from 800 mg onwards. PD effects were observed from the first dose level onwards with HER3 membranous protein down-regulation in skin and from 200 mg onwards in ontreatment tumor samples. Five pts (1 NSCLC, 2 CRC, 1 SCCHN, 1 BC) had a best response of SD. Confirmed SD (>16 weeks) was observed in 2 pts. One BC patient achieved a PR in 18 FDG-PET and significant shrinkage of non-target tumor lesions on CT scan. Conclusions: RG7116 is the first glycoengineered monoclonal anti-HER3 antibody in clinical development. RG7116 monotherapy was well tolerated, and demonstrated preliminary signs of clinical activity. Clinical trial information: NCT01482377.
Collapse
Affiliation(s)
- Didier Meulendijks
- Deptartment Clinical Pharmacology, Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, Amsterdam, Netherlands
| | | | - Emile E. Voest
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, Netherlands
| | - Maja J. De Jonge
- Department of Medical Oncology, Erasmus University Medical Center Daniel den Hoed Cancer Center, Rotterdam, Netherlands
| | - Stefan Sleijfer
- Erasmus MC, Department of Medical Oncology and Cancer Genomics Netherlands, Rotterdam, Netherlands
| | - Jan HM Schellens
- The Netherlands Cancer Institute-Antoni Van Leeuwenhoek Hospital, Amsterdam, Netherlands
| | - Tania Fleitas
- Department of Haematology and Medical Oncology, Institute of Health Research INCLIVA, University of Valencia, Valencia, Spain
| | | | | | - Alvaro Taus
- Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
| | | | - Marlene Thomas
- Research and Early Development, Roche Pharma, Penzberg, Germany
| | | | - Celine Adessi
- Research and Early Development, Roche Pharma, Basel, Switzerland
| | - Lilla Di Scala
- Research and Early Development, Roche Pharma, Basel, Switzerland
| | - Abiraj Keelara
- Research and Early Development, Roche Pharma, Basel, Switzerland
| | - Wolfgang Jacob
- Research and Early Development, Roche Pharma, Penzberg, Germany
| | - Martin Weisser
- Research and Early Development, Roche Pharma, Penzberg, Germany
| | | |
Collapse
|
40
|
Abstract
Traditional mechanical ventilation used tidal volumes (Vt) of between 10 to 15 ml/kg of body weight in order to achieve normal values of pH and partial pressure of carbon dioxide (PaCO2). Many clinicians today however, adopt lower volumes as a conservative ‘safe’ ventilation strategy in most mechanically ventilated patients. The method by which this is done varies between facilities, but anecdotally doctors use Vt of 6 to 8 ml/kg, and they commonly estimate these volumes at the bedside. This observational study was undertaken in a 23-bed level 3 intensive care unit at a metropolitan tertiary hospital in order to determine whether or not intensive care clinicians are accurately determining the Vt during mechanical ventilation which they purport to do. The primary outcome measure was the Vt being delivered at the time of observation. Thirty patients were recruited into the study, resulting in 55 observations of synchronised intermittent mandatory ventilation with autoflow mode ventilator settings. Although volumes between 6 to 8 ml/kg were recorded in 33 (60%) observations, more detailed exploration of the individual's clinical circumstances reflects that the actual dialled volumes were correct in all but two patients. Intensive care unit mortality was 13% (n=2) in those patients receiving higher than anticipated Vts (n=15). This study has demonstrated that while we achieve a protective ventilation strategy by adopting lower Vts in most mechanically ventilated patients, we should be constantly monitoring exactly what volume is being achieved, not just what is dialled up to be delivered.
Collapse
Affiliation(s)
- D. Dennis
- Intensive Care Unit, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - W. Jacob
- Intensive Care Unit, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
| | - P. V. Van Heerden
- Intensive Care Unit, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia
- University of Western Australia
| |
Collapse
|
41
|
Jacob W, Marsch R, Marsicano G, Lutz B, Wotjak CT. Cannabinoid CB1 receptor deficiency increases contextual fear memory under highly aversive conditions and long-term potentiation in vivo. Neurobiol Learn Mem 2012; 98:47-55. [DOI: 10.1016/j.nlm.2012.04.008] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2011] [Revised: 03/30/2012] [Accepted: 04/25/2012] [Indexed: 12/12/2022]
|
42
|
|
43
|
|
44
|
|
45
|
|
46
|
Jacob W, Yassouridis A, Marsicano G, Monory K, Lutz B, Wotjak CT. Endocannabinoids render exploratory behaviour largely independent of the test aversiveness: role of glutamatergic transmission. Genes, Brain and Behavior 2009; 8:685-98. [DOI: 10.1111/j.1601-183x.2009.00512.x] [Citation(s) in RCA: 70] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
47
|
|
48
|
Jacob W. Über die Weiterentwicklung der Diabetestherapie auf Grund klinischer und katamnestischer Ergebnisse im letzten Jahrzehnt. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0028-1120103] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
49
|
Jacob W, Gravius A, Pietraszek M, Nagel J, Belozertseva I, Shekunova E, Malyshkin A, Greco S, Barberi C, Danysz W. The anxiolytic and analgesic properties of fenobam, a potent mGlu5 receptor antagonist, in relation to the impairment of learning. Neuropharmacology 2009; 57:97-108. [PMID: 19426746 DOI: 10.1016/j.neuropharm.2009.04.011] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2009] [Revised: 04/20/2009] [Accepted: 04/22/2009] [Indexed: 11/18/2022]
Abstract
Fenobam [N-(3-chlorophenyl)-N'-(4,5-dihydro-1-methyl-4-oxo-1H-imidazole-2-yl)urea] was suggested to possess anxiolytic actions 30 years ago. Hoffmann-La Roche researchers recently reported that it is a selective and potent mGlu5 receptor antagonist, acting as a negative allosteric modulator. In the present study, we show that fenobam readily penetrates to the brain, reaching concentrations over 600 nM, clearly above the affinity for mGluR5 receptors. Fenobam (at 10, 30, and 100 mg/kg) did not affect horizontal locomotor activity in the open field test. Anxiolytic-like activity in the context freezing test was seen at 30 mg/kg, while fenobam was not active in the elevated plus maze test at the tested concentrations. Fenobam had antinociceptive actions in the formalin test at 10 and 30 mg/kg, but failed to attenuate mechanical allodynia in the chronic constriction injury model. Impairment of learning was revealed in the passive avoidance test at 30 mg/kg. Fenobam also impaired performance in both the Morris water maze and in the contextual fear conditioning test at the doses of 30 and 10 mg/kg, respectively. Prepulse inhibition, used as a model of psychomimetic activity, was not affected by fenobam at doses of up to 60 mg/kg. Our results indicate that the beneficial effects of fenobam occur in a similar dose range as the potential side-effects.
Collapse
Affiliation(s)
- Wolfgang Jacob
- In Vivo Pharmacology, Merz Pharmaceuticals GmbH, Frankfurt am Main, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kessler MS, Murgatroyd C, Bunck M, Czibere L, Frank E, Jacob W, Horvath C, Muigg P, Holsboer F, Singewald N, Spengler D, Landgraf R. Diabetes insipidus and, partially, low anxiety-related behaviour are linked to a SNP-associated vasopressin deficit in LAB mice. Eur J Neurosci 2008; 26:2857-64. [PMID: 18001282 DOI: 10.1111/j.1460-9568.2007.05917.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Following secretion from the posterior pituitary, the neuropeptide vasopressin (AVP) stimulates the kidney to retain water, and when released centrally it can contribute to anxiety- and depression-like behaviours. We hypothesized that CD1 mice bred for low trait anxiety (LAB) suffer from a deficit in AVP. Both osmotically stimulated peripheral secretion and intra-paraventricular nucleus (PVN) release of AVP were found decreased in LAB animals compared with normal anxiety (NAB) or high anxiety (HAB) controls. Consequently, in addition to their extreme non-anxiety, LAB mice showed signs of central diabetes insipidus (cDI), including increased fluid intake and reduced urine osmolality, as well as a pathological increase in plasma osmolality upon water deprivation. These cDI symptoms were attenuated by administration of a selective AVP V2 receptor agonist. A single nucleotide polymorphism (SNP) in exon 1 (C(+40)T) of the Avp gene of LAB animals causes an amino acid substitution in the signal peptide of the AVP precursor, and is likely to impair processing and trafficking of the precursor, as suggested by reduced axonal transport of AVP from the hypothalamic PVN, finally contributing to cDI symptoms and low trait anxiety. In an F2 panel, this SNP co-segregated with fluid intake and showed a partial contribution to low anxiety-related behaviour, indicated by its co-segregation with time spent on the open arms of the elevated plus-maze in a subset of F2 mice. Thus, the SNP-associated deficit in plasma and central AVP contributes to signs of cDI and, at least partially, to low trait anxiety, both features being typical of LAB animals.
Collapse
|